UBX - ユニティ―・バイオテクノロジ― (Unity Biotechnology Inc.)

UBXのニュース

   Unity Biotechnology Inc Shares Fall 0.7% Below Previous 52-Week Low - Market Mover  2021/12/29 07:51:05 Kwhen Finance
Unity Biotechnology Inc (UBX) shares closed 0.7% lower than its previous 52 week low, giving the company a market cap of $79M. The stock is currently down 73.7% year-to-date, down 75.2% over the past 12 months, and down 91.7% over the past five years. This week, the Dow Jones Industrial Average rose 3.9%, and the S&P 500 rose 4.9%. Trading Activity Trading volume this week was 97.1% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.8% The company's stock price performance over the past 12 months lags the peer average by 140.8% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   UNITY Biotechnology Reports Granting of New Employment Inducement Award  2021/12/22 13:00:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that from December 7, 2021, through December 21, 2021, the Compensation Committee of the Board of Directors (the Board) granted a new employee a stock-based award covering an aggregate of 4,500 shares of UNITY common stock, including options to purchase an aggregate of 4,500 shares of UNITY common stock. The stock-based award was granted pursuant to the UNITY 2020 Employment Inducement Incentive Plan, as amended, which was approved by the Board in March 2020 to provide for grants to newly hired employees as a material inducement for them to commence employment with UNITY in accordance with Nasdaq Stock Market Rule 5635(c)(4) .
   Does Unity Biotechnology Inc. (NASDAQ: UBX) Still Look Attractive After A -18.09% Selloff Last Week?  2021/12/17 13:30:00 Marketing Sentinel
During the last session, Unity Biotechnology Inc. (NASDAQ:UBX)’s traded shares were 1.21 million, with the beta value of the company hitting 0.12. At the end of the trading day, the stock’s price was $1.54, reflecting an intraday loss of -12.50% or -$0.22. The 52-week high for the UBX share is $9.78, that puts it down … Does Unity Biotechnology Inc. (NASDAQ: UBX) Still Look Attractive After A -18.09% Selloff Last Week? Read More »
   Wedbush Reaffirms Outperform Rating for Unity Biotechnology (NASDAQ:UBX)  2021/12/16 00:38:42 Transcript Daily
Unity Biotechnology (NASDAQ:UBX)s stock had its outperform rating reaffirmed by equities researchers at Wedbush in a research note issued on Wednesday, RTT News reports. They currently have a $4.00 target price on the stock. Wedbushs target price points to a potential upside of 127.27% from the stocks previous close. Other equities research analysts have also []
   Unity Biotechnology Inc. (NASDAQ: UBX) Stock Forecast: 12.00 USD Or More!  2021/11/25 20:00:00 Stocks Register
Unity Biotechnology Inc. (NASDAQ:UBX) shares, rose in value on Wednesday, 11/24/21, with the stock price down by -1.28% to the previous day’s close as strong demand from buyers drove the stock to $2.32. Actively observing the price movement in the last trading, the stock closed the session at $2.35, falling within a range of $2.26 … Unity Biotechnology Inc. (NASDAQ: UBX) Stock Forecast: 12.00 USD Or More! Read More »
   UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference  2021/08/16 20:03:00 Intrado Digital Media
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will present at the upcoming H.C. Wainwright Ophthalmology Virtual Conference.
   Unity Biotechnology EPS misses by $0.03  2021/08/10 21:16:15 Seeking Alpha
   UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates  2021/08/10 20:01:00 Intrado Digital Media
UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet age-related macular degeneration (AMD)
   UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease  2021/07/23 12:00:00 Intrado Digital Media
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325
   Takeaways On Unity Biotech''s Clinical Data From A Bull Analyst  2021/07/06 21:12:03 Benzinga
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX ). The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target. The Unity Biotech Takeaways: The release of preliminary clinical data from a Phase 1 study points to a transcendence of the reported favorable safety and tolerability profile of UBX1325, a small molecule Bcl-xL inhibitor, Fein said in a Tuesday note. The trials were designed to test the safety of UBX1325, not the efficacy, yet managed to show a Full story available on Benzinga.com
   UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease  2021/07/23 12:00:00 Intrado Digital Media
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325
   Takeaways On Unity Biotech''s Clinical Data From A Bull Analyst  2021/07/06 21:12:03 Benzinga
Positive results from primary clinical data regarding UBX1325 have H.C. Wainwright & Co. analysts bullish UNITY Biotechnology, Inc. (NASDAQ: UBX ). The Unity Biotech Analyst: Andrew Fein reaffirmed a Buy rating on shares of Unity Biotech with a $12 price target. The Unity Biotech Takeaways: The release of preliminary clinical data from a Phase 1 study points to a transcendence of the reported favorable safety and tolerability profile of UBX1325, a small molecule Bcl-xL inhibitor, Fein said in a Tuesday note. The trials were designed to test the safety of UBX1325, not the efficacy, yet managed to show a Full story available on Benzinga.com
   Unity Biotech''s UBX1325 Shows Initial Efficacy With Improved Vision, Structure In Vascular Eye Disease  2021/07/06 12:59:46 Benzinga
Unity Biotechnology Inc (NASDAQ: UBX ) has announced positive data from its Phase 1 safety study of UBX1325 in patients with diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) for whom anti-VEGF therapy was no longer considered beneficial. UBX1325 is a small molecule inhibitor of Bcl-xL and Full story available on Benzinga.com
   UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease  2021/07/06 11:00:00 Intrado Digital Media
Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325
   Unity Biotechnology Consensus Indicates Potential 64.1% Upside  2021/06/27 15:53:11 DirectorsTalk
Unity Biotechnology with ticker code (UBX) now have 7 analysts covering the stock with the consensus suggesting a rating of ''Hold''. The target price ranges between 12 and 4 with the average target price sitting at 6.86. With the stocks previous close at 4.18 this is indicating there is a potential upside of 64.1%. The day 50 moving average is 4.45 while the 200 day moving average is 5.81. The market cap for the company is $238m. Company Website: /> [stock_market_widget type="chart" symbol="UBX" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Unity Biotechnology, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company''s lead drug candidate include UBX1325, which is Phase I clinical trial for the treatment of age-related diseases of the eye, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. It is also developing UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications.

calendar